FY2024 EPS Estimates for Humacyte Cut by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Cantor Fitzgerald cut their FY2024 EPS estimates for Humacyte in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($1.41) per share for the year, down from their previous estimate of ($1.23). Cantor Fitzgerald has a “Overweight” rating and a $13.00 price target on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.18) per share.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

A number of other analysts have also recently issued reports on HUMA. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a report on Friday, October 18th. Benchmark reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. TD Cowen restated a “buy” rating and issued a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a research note on Wednesday. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $11.00.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $4.84 on Thursday. The firm has a market capitalization of $577.65 million, a PE ratio of -3.66 and a beta of 1.47. The company has a quick ratio of 5.41, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The company has a 50-day moving average price of $5.44 and a two-hundred day moving average price of $6.17. Humacyte has a twelve month low of $2.35 and a twelve month high of $9.97.

Insiders Place Their Bets

In other Humacyte news, CFO Dale A. Sander sold 39,389 shares of Humacyte stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.68, for a total value of $263,118.52. Following the transaction, the chief financial officer now directly owns 2,000 shares of the company’s stock, valued at $13,360. The trade was a 95.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. This trade represents a 5.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,084,153 shares of company stock valued at $6,869,996 over the last quarter. 11.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new position in shares of Humacyte in the second quarter valued at about $28,000. Concurrent Investment Advisors LLC bought a new stake in shares of Humacyte in the third quarter worth about $75,000. Principal Financial Group Inc. purchased a new position in Humacyte during the 2nd quarter valued at about $83,000. FORA Capital LLC bought a new position in Humacyte during the 3rd quarter valued at approximately $96,000. Finally, Profund Advisors LLC bought a new position in Humacyte during the 2nd quarter valued at approximately $97,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.